

**EKF Diagnostics Holdings plc
("EKF", the "Company")**

Shareholder update

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces that the Board of Directors have initiated a strategic review.

An independent committee of the Non-Executive Directors will lead the strategic review, chaired by Dr Kevin Wilson and consisting of Adam Reynolds, David Toohey and Doris Ann Williams.

The independent committee are committed to completing their review as soon as practicable.

Enquiries:

EKF Diagnostics Holdings plc	Tel: 029 2071 0570
David Evans, Executive Chairman	Mob: 07740 084 452
Dr Kevin Wilson, Chair of the independent committee	Mob: 07796 697 594

Panmure Gordon (UK) Limited	
Robert Naylor (Corporate Finance)	Tel: 020 7886 2714
Paul Fincham (Corporate Finance)	Tel: 020 7886 2713
Maisie Atkinson (Corporate Broking)	Tel: 020 7886 2905
Michael Seabrook (Sales)	Tel: 020 7886 2704

Walbrook PR Limited	Tel: 020 7933 8780 or ekf@walbrookpr.com
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	Mob: 07584 391 303

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market. In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCUGUCCUPAGAG Anonymous (not verified) Shareholder update 22629512 A Thu, 04/02/2015 - 07:00 Company Announcement - General EKF